# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CytoSorbents shares are trading higher by 20% during Tuesday's session. The company entered into a new $20 million credit f...
Proceeds from the facility are intended to provide non-dilutive working capital to support the Company's ongoing global Cyt...
The removal of the antithrombotic drugs Brilinta® (ticagrelor, AstraZeneca) and Xarelto® (rivaroxaban, Janssen/Bayer) during ca...
B. Riley Securities analyst Yuan Zhi reiterates CytoSorbents (NASDAQ:CTSO) with a Buy and maintains $3 price target.
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 2...
HC Wainwright & Co. analyst Sean Lee reiterates CytoSorbents (NASDAQ:CTSO) with a Neutral and maintains $1 price target.
HC Wainwright & Co. analyst Sean Lee reiterates CytoSorbents (NASDAQ:CTSO) with a Neutral and maintains $1 price target.
CytoSorbents (NASDAQ:CTSO) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) ...